Navigation Links
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Date:3/31/2008

- New Data from SPIRIT II Show Continued Low Rates of MACE with XIENCE V -

CHICAGO, March 31 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT II clinical trial demonstrated continued positive clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System out to two years, including an observed 40 percent reduction in major adverse cardiac events (MACE) and an observed 44 percent reduction in vessel retreatment (ischemia-driven target lesion revascularization, TLR) compared to the TAXUS(R) paclitaxel-eluting coronary stent system. The two-year results from the SPIRIT II trial were presented at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit.

SPIRIT II is a 300-patient randomized clinical trial, which was conducted in Europe and Asia Pacific to support the launch of XIENCE V outside the United States. In SPIRIT II, XIENCE V demonstrated the following key results:

-- In an analysis of major adverse cardiac events (MACE), XIENCE V

demonstrated an observed 40 percent reduction in MACE compared to

TAXUS at two years (6.6 percent for XIENCE V vs. 11.0 percent for

TAXUS). MACE is an important clinical measure of patient outcomes,

defined as cardiac death, heart attack (myocardial infarction or MI),

or ischemia-driven target lesion revascularization.

-- XIENCE V demonstrated an observed 44 percent reduction in

ischemia-driven target lesion revascularization (TLR driven by lack of

blood supply) compared to TAXUS at two years (3.8 percent for XIENCE V

vs. 6.8 percent for TAXUS).

-- Rates of definite/probable stent thrombosis under the Dublin/Academic

Research Consortium (ARC) definition were 0.9 percent for XIENCE V and

1.4 percent for TAXUS at two years. The ARC definition of late-stent

thrombosis was developed to eliminate variability in the definitions

across various
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
4. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
5. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- Research and Markets ( ... "MRI Systems Market to 2020 - Focus ... Driven by Developing Economies" report to their ... - Focus on Patient Comfort and Operational Efficiency, ... market, competitive landscape, and trends for three MRI ...
(Date:8/4/2015)...  The Pittsburgh Life Sciences Greenhouse (PLSG), the region,s ... one of its portfolio companies, Medrobotics Corporation, has received ... Robotic System in the U.S.  "I ... said John W. Manzetti , president and CEO ... since spinning out of The Robotics Institute at Carnegie ...
(Date:8/4/2015)... PARK, N.J. , Aug. 4, 2015 ... with University of Massachusetts Medical School,s Clinical ... and support regarding clinical protocols and therapy ... Platform. Specialty medication therapy ... and helps to ensure optimal patient outcomes ...
Breaking Medicine Technology:Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3
... Schering-Plough,Corporation (NYSE: SGP ), a leader in ... large Phase III studies of boceprevir, its,investigational oral ... hepatitis C virus (HCV) genotype 1. One study,will ... other in patients,who failed prior treatment (relapsers and ...
... Among Group of Leading Cancer Centers ... Presenting Cryoablation Data, ... ), an innovative medical device company focused on the,development of ... and tumor ablation, announced today,that cryoablation, a minimally invasive method ...
Cached Medicine Technology:Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 2Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 3Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 4Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 5Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 6Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 7Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 8Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 9Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 10Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 2Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 4
(Date:8/4/2015)... , ... August 04, 2015 , ... ... products, announces the Assisted Dumbbell Bench Rack, a fitness invention that eliminates the ... , "The Gym, Health and Fitness Clubs industry is worth $30 billion," says ...
(Date:8/4/2015)... ... August 04, 2015 , ... The United Nations ... and rights in Indonesia for a select group of U.S.-based journalists during the ... Indonesia and attend the International Conference on Family Planning in Bali. , ...
(Date:8/4/2015)... ... ... An article published July 27th by the Providence Journal detailed ... people to lose weight. Specifically the study compared control patients with those who were ... financial incentive to the overall incentive of increased health. According to Michael Feiz, M.D., ...
(Date:8/4/2015)... Santa Barbara, CA (PRWEB) , ... August 04, ... ... if you are suffering from underarm sweat. Evolutions Medical & Day Spa in ... called miraDry, the only non-invasive, FDA cleared treatment that permanently eliminates sweat and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s 4th Annual ... 3 – 4, 2015, at UC San Diego, will explore innovations that farmers ... access, and manage resources efficiently against the dueling backdrop of a lingering Western ...
Breaking Medicine News(10 mins):Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3
... /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ... devices in China with a rapidly growing,international presence, ... for the first quarter ended March 31, 2008, ... Mindray,s management will hold an earnings,conference call at ...
... They either miss shots or get them at the wrong ... -- New numbers show that more than a quarter of ... aged 19 months to 35 months found that missed doses ... miss-timed doses are also an issue, according to a study ...
... Increase of 47% Over Prior Year Period and ... Exceeds Guidance ... ) today reported the results for its third quarter and nine,months of ... Total revenues increased 9% to a record,level of $20.6 million in the ...
... Presentation System Designed for Today,s Younger Market, ... in,providing long-term care insurance sales, marketing and presentation,solutions ... of,simplifyingLTC, a LTCI presentation system designed specifically for,today,s ... the risk of long-term care in,a language younger ...
... Driven by International Growth and InLight Product Sales, GLENWOOD, ... recognized leader in personal and environmental radiation,monitoring, today reported that ... the three and six months ended March 31, 2008., ... record $23.7 million on InLight equipment sales and ...
... Deliver ... Advanced Imaging Services, POWAY, Calif., April ... of medical diagnostic imaging systems,and services to physicians, offices, hospitals ... agreement with the University of,Chicago Medical Center (Medical Center) to ...
Cached Medicine News:Health News:Mindray to Report First Quarter 2008 Financial Results on May 7, 2008 2Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 2Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 3Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 2Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 3Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 4Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 5Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 6Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 7Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 8Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 9Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 10Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 11Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 12Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 13Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 14Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 15Health News:SellingLTC.com Develops simplifyingLTC 2Health News:Landauer, Inc. Reports Record Results for Second Quarter 2Health News:Landauer, Inc. Reports Record Results for Second Quarter 3Health News:Landauer, Inc. Reports Record Results for Second Quarter 4Health News:Landauer, Inc. Reports Record Results for Second Quarter 5Health News:Landauer, Inc. Reports Record Results for Second Quarter 6Health News:Landauer, Inc. Reports Record Results for Second Quarter 7Health News:Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement 2Health News:Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement 3Health News:Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement 4
...
... antimony pH catheters are designed for patient comfort ... catheters are number marked at 5cm intervals and ... sixteen individual models are available spanning most clinical ... multi-use models with one or two sensors., ...
... designed using established technology providing a ... ,Working with pH catheters with ... multi-use catheter is used the Hellige ... the skin.,NOTE: ,Medtronic pH measurement systems ...
FLEXILOG spare part....
Medicine Products: